Yucel OE, et al. - Experts assessed over 6 months, the effectiveness of intravitreal ranibizumab (IR), aflibercept (IA) and dexamethasone implant (IDI) in eyes with macular edema (ME) secondary to non-ischemic central retinal vein occlusion (CRVO). Due to non-ischemic CRVO, IR and IA could be preferred treatment for ME as visual improvement remained the primary ophthalmological objective. Findings suggested that the impact of IDI on CMT and the need for fewer injections were the most important advantages of IDI. Researchers noted a greater chance of an increase in IOP and the formation of cataract in IDI-treated eyes.